We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. Show more
TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. Zura Bio...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -3.35195530726 | 1.79 | 1.835 | 1.6 | 364849 | 1.69351082 | CS |
4 | -0.83 | -32.421875 | 2.56 | 2.64 | 1.6 | 342538 | 1.97470119 | CS |
12 | -2.47 | -58.8095238095 | 4.2 | 4.85 | 1.6 | 490479 | 2.62988662 | CS |
26 | -2.24 | -56.4231738035 | 3.97 | 5.07 | 1.6 | 449965 | 3.41432456 | CS |
52 | -1.51 | -46.6049382716 | 3.24 | 6.35 | 1.6 | 364109 | 3.44535842 | CS |
156 | -6.27 | -78.375 | 8 | 37.55 | 1.6 | 359362 | 5.97770157 | CS |
260 | -6.27 | -78.375 | 8 | 37.55 | 1.6 | 359362 | 5.97770157 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions